Virax Biolabs CEO James Foster speaks to Proactive following the company’s July 21 IPO on the Nasdaq, which he said provides the best platform for an innovative biotech company like Virax to raise its exposure and create liquidity.
After pricing the listing at $5 per share, Virax’s shares rose as high as $20 on its market debut.
“It’s rare that you see that in a market like this,” Foster told Proactive. “We just want to keep up that momentum and keep things going.”
“We’re really confident in our technology; we’re really confident about what we’re doing and the mission that we’re on.”